To summarise, while [177Lu]Lu-DOTATATE shows great promise for treatment of neuroblastoma, identifying combination strategies to overcome insufficient or heterogenous target expression and to lower radiation-induced toxicity is necessary and p53 stabilisation may provide a unique opportunity to potentiate radiotherapy effects in this patient group. This evidence concerns the gene TP53 and neuroblastoma.